| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
158.12(B) |
| Last
Volume: |
2,436,955 |
Avg
Vol: |
2,722,982 |
| 52
Week Range: |
$214.27 - $324.56 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 499 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
12,096 |
21,654 |
43,486 |
| Total Sell Value |
$0 |
$3,300,412 |
$5,808,718 |
$11,189,871 |
| Total People Sold |
0 |
2 |
3 |
6 |
| Total Sell Transactions |
0 |
2 |
3 |
9 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gordon Murdo |
EVP, Global Commercial Ops |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
4,237 |
55,348 |
|
- |
|
| Griffith Peter H. |
EVP & CFO |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,814 |
32,598 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,559 |
64,877 |
|
- |
|
| Holley Charles M |
Director |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
170 |
7,040 |
|
- |
|
| Ishrak Omar |
Director |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
138 |
2,462 |
|
- |
|
| Drake Michael V |
Director |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
138 |
961 |
|
- |
|
| Gordon Murdo |
EVP, Global Commercial Ops |
• • – |
2023-04-30 |
4 |
D |
$239.74 |
$174,531 |
D/D |
(728) |
51,111 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2023-04-30 |
4 |
D |
$239.74 |
$11,268 |
D/D |
(47) |
7,084 |
|
- |
|
| Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
• • – |
2023-04-30 |
4 |
D |
$239.74 |
$159,187 |
D/D |
(664) |
37,377 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2023-04-30 |
4 |
D |
$239.74 |
$159,667 |
D/D |
(666) |
51,713 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2023-04-30 |
4 |
D |
$239.74 |
$529,346 |
D/D |
(2,208) |
633,194 |
|
- |
|
| Griffith Peter H. |
EVP & CFO |
• • – |
2023-04-30 |
4 |
D |
$239.74 |
$139,768 |
D/D |
(583) |
28,784 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2023-04-30 |
4 |
D |
$239.74 |
$158,228 |
D/D |
(660) |
61,318 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2023-04-30 |
4 |
D |
$239.74 |
$17,501 |
D/D |
(73) |
13,705 |
|
- |
|
| Miller Derek |
SVP, Human Resources |
• • – |
2023-04-30 |
4 |
D |
$239.74 |
$11,987 |
D/D |
(50) |
6,560 |
|
- |
|
| Louie Linda H. |
VP, Finance & CAO |
• • – |
2023-04-30 |
4 |
D |
$239.74 |
$6,473 |
D/D |
(27) |
9,579 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2023-03-17 |
4 |
D |
$234.57 |
$3,277,177 |
D/D |
(13,971) |
635,402 |
|
- |
|
| Griffith Peter H. |
EVP & CFO |
• • – |
2023-03-17 |
4 |
D |
$234.57 |
$798,242 |
D/D |
(3,403) |
29,367 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2023-03-17 |
4 |
D |
$234.57 |
$933,119 |
D/D |
(3,978) |
52,379 |
|
- |
|
| Gordon Murdo |
EVP, Global Commercial Ops |
• • – |
2023-03-17 |
4 |
D |
$234.57 |
$933,119 |
D/D |
(3,978) |
51,839 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2023-03-17 |
4 |
D |
$234.57 |
$79,519 |
D/D |
(339) |
13,778 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2023-03-17 |
4 |
D |
$234.57 |
$910,366 |
D/D |
(3,881) |
61,978 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2023-03-17 |
4 |
D |
$234.57 |
$56,531 |
D/D |
(241) |
7,103 |
|
- |
|
| Louie Linda H. |
VP, Finance & CAO |
• • – |
2023-03-17 |
4 |
D |
$234.57 |
$22,519 |
D/D |
(96) |
9,606 |
|
- |
|
| Miller Derek |
SVP, Human Resources |
• • – |
2023-03-17 |
4 |
D |
$234.57 |
$75,532 |
D/D |
(322) |
6,610 |
|
- |
|
2150 Records found
|
|
Page 4 of 86 |
|
|
0.60 (0.22%) 
